Patrick W. McLaughlin, MD, discusses the balance of cure versus quality-of-life when treating prostate cancer patients. He details his approach to ensuring optimal patient-preferred outcomes using physician-as-advocate decision-making, as well as individual anatomical and tumor characteristics in guiding treatment planning.
Read More
Patrick W. McLaughlin, MD, discusses the limitations of evidence that provide the basis for the United States Preventive Services Task Force’s (USPSTF’s) negative gradings for PSA screening. He argues that in the modern era, with the currently-available curative therapy for most lethal prostate cancers, intensive screening can allow early enough detection to provide patients opportunities for a cure.
Read More
Jason M. Hafron, MD, discusses the growing presence of millennials in the workplace, particularly in urologic practices. He emphasizes that millennial physicians’ have the ability to advance the urologic field by applying their talents and perspectives regarding technology, efficiency, and physician/patient relationships.
Read MoreMark A. Moyad, MD, MPH, the Jenkins/Pokempner Director of Preventive & Complementary Medicine at the University of Michigan Medical Center, discusses new findings concerning supplements in prostate cancer treatment and the best natural alternatives.
Read More
Matt T. Rosenberg, MD, discusses treating of lower urinary tract symptoms (LUTS) through a framework of inhibiting overproduction of urine by the kidneys. In this dual-presentation, he describes behavioral modifications as well as pharmacologic agents for the management of overactive bladder (OAB) and nocturia.
Read More